Feasibility of Using the "CGM GUARDIAN 2" Interstitial Fluid Glucose Measurement System in
Glycemic imbalances are very common in shock patients admitted to intensive care units. A blood glucose control every 2 hours is routinely performed in patients requiring insulin therapy. In practice, we use a protocol and management software called "CPG" (Personalized Control of Blood Glucose). This involves taking ca
| Condition(s) | Hyperglycemia, Hypotension, Shock, Septic |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | Glycemic imbalances are very common in shock patients admitted to intensive care units. A blood glucose control every 2 hours is routinely performed in patients requiring insulin therapy. In practice, we use a protocol and management software called "CPG" (Personalized Control of Blood Glucose). This involves taking capillary samples from the fingertips. In addition to the pain generated, local haematomas and sensitivity disorders have been described. Night-time sampling also leads to repeated awakenings. The "CGM GUARDIAN 2" system has been validated for the measurement of glucose in interstitial fluid in insulin-dependent diabetic patients. An electrode is placed on the patient's abdomen or arm for up to 6 days. This electrode consists of a needle that is inserted subcutaneously only dur |
| Who can participate | Inclusion Criteria: * Patient in septic shock * Arterial hypotension requiring noradrenaline * Hyperglycaemia requiring insulin therapy Exclusion Criteria: * Patients under guardianship, curatorship or deprived of liberty * Pregnant or breastfeeding women |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Centre Hospitalier Universitaire de Nice |
| Locations | Nice, France |
| Start date | 2023-09-11 |
| NCT ID | NCT04910841 |
| Official listing | https://clinicaltrials.gov/study/NCT04910841 |